Wall Street analysts forecast that AtriCure, Inc. (NASDAQ:ATRC) will report earnings per share (EPS) of ($0.21) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for AtriCure’s earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.17). AtriCure reported earnings per share of ($0.27) in the same quarter last year, which suggests a positive year over year growth rate of 22.2%. The business is expected to issue its next earnings results on Tuesday, February 27th.

On average, analysts expect that AtriCure will report full year earnings of ($0.96) per share for the current fiscal year, with EPS estimates ranging from ($1.00) to ($0.92). For the next financial year, analysts anticipate that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.86) to ($0.61). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow AtriCure.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company had revenue of $42.20 million for the quarter, compared to analysts’ expectations of $43.44 million. During the same period in the previous year, the firm posted ($0.21) EPS. AtriCure’s revenue was up 10.1% compared to the same quarter last year.

Several equities research analysts recently issued reports on the company. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 price objective on shares of AtriCure in a report on Monday, October 9th. Needham & Company LLC lowered their price objective on AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. ValuEngine cut AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a report on Wednesday, November 29th. Finally, Zacks Investment Research upgraded AtriCure from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. AtriCure has an average rating of “Hold” and a consensus target price of $25.00.

In related news, Director B Kristine Johnson bought 1,500 shares of the stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $18.36 per share, for a total transaction of $27,540.00. Following the acquisition, the director now directly owns 10,969 shares in the company, valued at approximately $201,390.84. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO M. Andrew Wade sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total value of $36,820.00. The disclosure for this sale can be found here. Insiders own 11.90% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Royce & Associates LP boosted its holdings in shares of AtriCure by 12.7% during the 2nd quarter. Royce & Associates LP now owns 302,400 shares of the medical device company’s stock worth $7,333,000 after purchasing an additional 34,100 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of AtriCure by 45.5% during the 2nd quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock worth $19,993,000 after purchasing an additional 257,949 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of AtriCure by 1.4% during the 2nd quarter. Victory Capital Management Inc. now owns 1,319,475 shares of the medical device company’s stock worth $31,998,000 after purchasing an additional 18,536 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in AtriCure in the second quarter valued at approximately $315,000. Finally, State Street Corp lifted its holdings in AtriCure by 4.0% in the second quarter. State Street Corp now owns 617,405 shares of the medical device company’s stock valued at $14,971,000 after acquiring an additional 23,790 shares during the last quarter. Institutional investors and hedge funds own 86.17% of the company’s stock.

Shares of AtriCure (NASDAQ:ATRC) opened at $18.52 on Monday. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. AtriCure has a twelve month low of $14.78 and a twelve month high of $25.18.

ILLEGAL ACTIVITY WARNING: “-$0.21 Earnings Per Share Expected for AtriCure, Inc. (ATRC) This Quarter” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/04/0-21-earnings-per-share-expected-for-atricure-inc-atrc-this-quarter.html.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.